We are live on ! Find out more
HVC

Healthcare Value Capital Portfolio holdings

AUM $50.7M
1-Year Est. Return 24.72%
This Fund
S&P 500
This Quarter Est. Return
+30.39%
1 Year Est. Return
+24.72%
3 Year Est. Return
+18.99%
5 Year Est. Return
+98.49%
10 Year Est. Return
–
AUM
$82.5M
AUM Growth
+$14.4M
Cap. Flow
-$5.05M
Cap. Flow %
-6.12%
Top 10 Hldgs %
85.52%
Holding
33
New
3
Increased
2
Reduced
3
Closed
7

Top Buys

Rank Stock Value
1
ARLZ
Aralez Pharmaceuticals Inc.
ARLZ
+$1.79M

Top Sells

Rank Stock Value
1
AGN
Allergan plc
AGN
+$2.68M
2
ANIP icon
ANI Pharmaceuticals
ANIP
+$2.43M
3
AMRI
Albany Molecular Research Inc
AMRI
+$1.46M
4
SRNE
Sorrento Therapeutics, Inc.
SRNE
+$269K

Sector Composition

Rank Sector Weight
1 Healthcare 64.22%
2 Miscellaneous 35.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VIRX
26
CALL
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$82K 0.1%
714
– –
ACAD icon
27
PUT
Acadia Pharmaceuticals
ACAD
$5.12B
– –
-20,000
Closed -$559K
BIS icon
28
CALL
ProShares UltraShort NASDAQ Biotechnology
BIS
$1.77M
– –
-6,250
Closed -$2.18M
GSK icon
29
CALL
GSK
GSK
$101B
– –
-40,000
Closed -$2.03M
EGRX
30
CALL
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
– –
-50,000
Closed -$2.02M
SRNE
31
DELISTED
Sorrento Therapeutics, Inc.
SRNE
– –
-50,000
Closed -$269K
LCI
32
CALL
DELISTED
Lannett Company, Inc.
LCI
– –
-12,500
Closed -$897K
AGN
33
DELISTED
Allergan plc
AGN
– –
-10,000
Closed -$2.68M
1
2

Similar funds

C
Castlelake Minneapolis, Minnesota $48.5M AUM 87.77% 1-Year Est. Return
CC
Cedar Capital Barrington, Illinois $54.9M AUM 33.3% 1-Year Est. Return
FCOI
FirstMark Capital OF II New York $44.1M AUM 18.15% 1-Year Est. Return
FCOI
FirstMark Capital OF I New York $43.1M AUM 6.31% 1-Year Est. Return
BI
BCBSM Inc Eagan, Minnesota $42.4M AUM 0.4% 1-Year Est. Return
KC
Kelso & Company New York $42.3M AUM
SCIM
Spring Creek Investment Management Philadelphia, Pennsylvania $42.3M AUM 31.86% 1-Year Est. Return
MCP
Moab Capital Partners Southampton, New York $41M AUM 33.21% 1-Year Est. Return

Healthcare Value Capital's Q2 2016 Portfolio in Review

As of Q2 2016, Healthcare Value Capital held 33 positions worth $82.5M, up 21% from $68.1M the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Healthcare Value Capital withdrew a net $5.05M in Q2 2016, closing 7 positions and reducing 3 holdings. Its most notable exit was Allergan plc, an estimated $2.68M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 64% of assets, down from 70% a quarter earlier, followed by Miscellaneous.

Against the trend, Healthcare Value Capital added an estimated $1.79M to Aralez Pharmaceuticals Inc..

  • Healthcare Value Capital added most to Aralez Pharmaceuticals Inc. in Q2 2016, an estimated $1.79M increase.
  • Healthcare Value Capital's biggest Q2 2016 reduction was ANI Pharmaceuticals, cutting an estimated $2.43M.
  • Healthcare Value Capital fully exited Allergan plc in Q2 2016, selling an estimated $2.68M.
  • Healthcare Value Capital's ten largest holdings make up 86% of its $82.5M portfolio in Q2 2016.
  • Healthcare Value Capital opened 3 new positions and closed 7 in Q2 2016.
  • Healthcare Value Capital's portfolio value rose 21% quarter-over-quarter to $82.5M.

Based on Healthcare Value Capital's 13F filing for Q2 2016, filed 15 Aug 2016.